Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, ...
Inc to "neutral" from "overweight" on Wednesday, citing concerns over waning growth prospects as subscription revenue and bookings continue to decrease.